Wanbangde Pharmaceutical Holding Group002082.SZValuation Analysis

As of Oct 19, 2026, Wanbangde Pharmaceutical Holding Group (002082.SZ) trades at a negative P/E (-59.96x, due to a recent net loss), P/B of 2.74x, P/S of 5.98x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 70th percentile over the trailing 10Y window (vs. 73rd percentile over 3Y); P/S sits at the 93rd percentile over the trailing 10Y window (vs. 79th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 58th percentile within its industry and the 55th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Wanbangde Pharmaceutical Holding Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.